Story perspectives

Hope and Caution: CAR-T Therapy Trial for MS Begins

3/15/2026

Summary

Story summary

Grace Miller, a 46-year-old from Fishers, Indiana, is participating in a Cleveland Clinic CAR-T trial for multiple sclerosis (MS).
The therapy, which has shown promise in cancer, targets overactive B cells implicated in worsening MS symptoms.
Experts caution that CAR-T may not prove more effective than existing MS treatments.
Risks include cytokine release syndrome and neurotoxicity, while researchers seek therapies that repair neurological damage and better reveal MS progression.

1 of 1

Story summary

Grace Miller, a 46-year-old from Fishers, Indiana, is participating in a Cleveland Clinic CAR-T trial for multiple sclerosis (MS).
The therapy, which has shown promise in cancer, targets overactive B cells implicated in worsening MS symptoms.
Experts caution that CAR-T may not prove more effective than existing MS treatments.
Risks include cytokine release syndrome and neurotoxicity, while researchers seek therapies that repair neurological damage and better reveal MS progression.